TSNAX and neoplasm: Thus, structure-based design of small molecules that bind to the lower part of α3, α5, α6, and α7 helices of TRAX can be developed as novel agents for Globo H-targeted therapy to inhibit the angiogenesis in tumor microenvironments mediated by GHCer.